Media and News

PharmaNova Invited to Speak at the Controlled Release Society (CRS) Soapbox Session Innovations Sunday Series in Portland, Oregon, July 11, 2010

June 2, 2010

PharmaNova Invited to Speak at the Controlled Release Society (CRS) Soapbox Session Innovations Sunday Series in Portland, Oregon, July 11, 2010

Dr. Deepak Thassu of PharmaNova Inc., Victor, NY, has been invited to present PharmaNova’s NovaSperse™ technology at the CRS Innvovations Sunday Soapbox Session II, “Smart Drug Nanoparticles” on July 11 in Portland, Oregon at the Oregon Convention Center.  The Soapbox Sessions introduce the latest, most novel technologies, products, and services for controlled delivery in bioactive materials, consumer and diversified products, and animal health.  Dr. Thassu, VP Pharmaceutical Development, is an inventor of multiple US and EU drug delivery formulation patents and is the author and/or editor of several books and chapters on nanomedicine drug delivery.  PharmaNova’s NovaSperse℠ technology is based on de novo creation of controlled particle size of varying specificity.  Controlled release is a research discipline whose future depends on a thorough understanding of the interactions between the delivery system and the biological or environmental barriers to delivery of active substances. 

 

About CRS

CRS is an international organization which serves 3,000 members from more than 50 countries; the annual meeting attracts numerous industry representatives, scientists, academia, and international regulatory agencies.

For more information about the Controlled Release Annual Meeting see:   http://www.controlledrelease.org/main/about/default.cfm

About PharmaNova

PharmaNova Inc. is a privately held pharmaceutical company.  Our product candidates are derived from the re‐positioning and enhancement of known drugs using our proprietary NovaSperse℠ nanoparticle technology platform. We address low risk, fast to market products in areas of clear medical need and generate revenue from partnering and licensing strategies with commercialization partners and clients worldwide. PharmaNova also conducts contractual formulation development work applying NovaSperse technology to client‐owned products and compounds to support new product development or the extended life cycle management of existing products.  PharmaNova has other new product candidates in various stages in its development pipeline.   Our focus is on the development of novel, improved nanoparticle formulations of ophthalmic and anti-infective products.


Members of the media or for further information, please contact Tom Parker, Vice President Commercial Affairs:
tom.parker@pharmanovaco.com, (1) 585 413-4721.

 



« Back to Media

Member of the media wishing to learn more about Pharmanova should contact:
Rafael Larramendi, President | ral@rochester.rr.com | (585) 919 -9649.